Zydus Lifesciences has received approval from the DCGI to initiate two Phase III clinical trials for Zintrodiazine, a novel anti-malarial candidate. Developed in collaboration with Medicines for Malaria Venture (MMV), this treatment aims to provide a robust alternative to current artemisinin-based therapies. The trials will evaluate the efficacy, safety, and tolerability of the drug in 1,041 total patients suffering from uncomplicated malaria caused by P. falciparum and P. vivax.
Advancing the Fight Against Malaria
On April 25, 2026, Zydus Lifesciences announced a major milestone in its research and development pipeline. The company secured authorization to commence Phase III clinical trials for Zintrodiazine, an innovative anti-malarial compound designed to combat both standard and drug-resistant strains of malaria. This development is part of a long-term collaboration with Medicines for Malaria Venture (MMV), established in 2016 to address the rising threat of resistance to current front-line therapies.
Details of the Clinical Trials
The research program consists of two multi-centre, randomised, and assessor-blind studies to assess the efficacy and safety of orally administered Zintrodiazine:
- P. falciparum Study: Involving 651 patients, this trial focuses on efficacy measured by PCR-adjusted adequate clinical and parasitological response (ACPR).
- P. vivax Mono-infection Study: Involving 390 patients, this trial aims to confirm the treatment’s effectiveness in addressing this specific malaria strain.
Key endpoints for both studies include measuring parasite clearance time, fever clearance time, and the monitoring of new infections or recrudescence.
Addressing a Critical Global Challenge
With over 1,80,000 people diagnosed with malaria in India last year alone, the need for new treatment options is urgent. The rise of partial resistance to artemisinin derivatives—the current backbone of malaria treatment—poses a significant global health risk. By developing Zintrodiazine as part of a new combination therapy, Zydus Lifesciences aims to provide a reliable and effective solution for patients worldwide, reaffirming its commitment to advancing healthcare through pathbreaking scientific innovation.
Source: BSE
